Neurocrine Biosciences, Inc. (NBIX)
- Previous Close
133.66 - Open
140.62 - Bid 140.06 x 100
- Ask 140.29 x 100
- Day's Range
139.22 - 145.00 - 52 Week Range
89.04 - 148.37 - Volume
1,567,039 - Avg. Volume
880,037 - Market Cap (intraday)
14.09B - Beta (5Y Monthly) 0.28
- PE Ratio (TTM)
56.72 - EPS (TTM)
2.47 - Earnings Date May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 29, 1995
- 1y Target Est
151.96
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
www.neurocrine.com1,400
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: NBIX
Performance Overview: NBIX
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NBIX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NBIX
Valuation Measures
Market Cap
14.11B
Enterprise Value
13.50B
Trailing P/E
56.78
Forward P/E
27.17
PEG Ratio (5yr expected)
0.46
Price/Sales (ttm)
7.51
Price/Book (mrq)
6.32
Enterprise Value/Revenue
7.16
Enterprise Value/EBITDA
37.72
Financial Highlights
Profitability and Income Statement
Profit Margin
13.23%
Return on Assets (ttm)
8.78%
Return on Equity (ttm)
12.68%
Revenue (ttm)
1.89B
Net Income Avi to Common (ttm)
249.7M
Diluted EPS (ttm)
2.47
Balance Sheet and Cash Flow
Total Cash (mrq)
1.03B
Total Debt/Equity (mrq)
20.63%
Levered Free Cash Flow (ttm)
405.08M
Research Analysis: NBIX
Company Insights: NBIX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: NBIX
NBIX: Lowering target price to $140.00
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $140.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetNBIX: Raising target price to $146.00
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $146.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetNBIX: Lowering target price to $145.00
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $145.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetNBIX: What does Argus have to say about NBIX?
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $148.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target